literature

HIV mutation literature information.

Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.

PMID: 31430369 2019 The Journal of antimicrobial chemotherapy

Method: Primary PI-R substitutions were D30N, V32I, M46I/L, I47V/A, G48V, I50V/L, I54M/L, Q58E, T74P, L76V, V82A/F/L/S/T, N83D, I84V, N88S

Result: PI-R substitutions were observed in 10% (55/543), with M46I/L (4.1%, 22/543) and L90M (2.4%, 13/543) most frequently detected.

Table: M46I/L

Analysis of HIV-1 diversity, primary drug resistance and transmission networks in Croatia.

PMID: 31754119 2019 Scientific reports

Result: The sequence originating from the UK had a similar mutation pattern with additional SDRMs (PI: M46L, V82A and NRTI: T215Y).

Discussion: Phylogenetic inference indicated a transmission link with one UK sequence with a similar mutation pattern, PI: V32I, M46L, I47A, V82A + NRTI: T215Y + NNRTI: L100I, K103N.

Genetic diversity and antiretroviral resistance-associated mutation profile of treated and naive HIV-1 infected patients from the Northwest and Southwest regions of Cameroon.

PMID: 31751428 2019 PloS one

Result: Major protease inhibitor mutations were present in 3 (1.3%, 95% CI: 0.3-3.6%) of the sequences occurring as I54T-V82A, M46I and M46LV.

Result: Mutations M46I and M46LV demonstrated potential low-level resistance to saquinavir, indinavir, fosamprenavir, lopinavir and atazanavir (Fig 3).

Sustained virological response and drug resistance among female sex workers living with HIV on antiretroviral therapy in Kampala, Uganda: a cross-sectional study.

PMID: 31266818 2019 Sexually transmitted infections

Table: M46L

National survey of pre-treatment HIV drug resistance in Cuban patients.

PMID: 31479466 2019 PloS one

Table: M46I/L

Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study.

PMID: 31622432 2019 PloS one

Method: Participants with a history of genotypic/phenotypic drug resistance to protease inhibitors (PIs) or with HIV-1 genotypic drug resistance to PIs at baseline (including D30N, M46I/L, I47V/A, G48V, I50L, I54M/L, Q58E, T74P, L76V, V82A/F/L/T/S, N83D, I84V, N88S, or L90M) were excluded, despite any reported effects of PI resistance or resistance

[Genetic analysis of the mutations in HIV-1 infected population in Ecuador].

PMID: 29652972 2018 Revista chilena de infectologia

Abstract: Results The most frequent mutations were M184V/I, K101E/P/H, K103N/S, D30N, M46L/I, I54L/M, V82T/F/A/S/L and L90M in adults and F77L, K103N/S, M46L/I, V82T/F/A/S/L and L90M in children.

HIV-1 transmission networks across Cyprus (2010-2012).

PMID: 29684083 2018 PloS one

Abstract: There were only three newly diagnosed patients with transmitted drug resistant HIV-1 strains, one study subject from the United Kingdom infected with subtype B strain and one from Romania with sub-subtype A2 strain, both with PI drug resistance mutation M46L and one from Greece with sub-subtype A1 with non-nucleoside reverse transcriptase inhibitors (NNRTI) drug resistance mutation K103N.

Result: Specifically, there was one patient (CY369) infected with an HIV-1 strain with a non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance mutation (K103N) and two patients (CY274 and CY314) with a protease inhibitor (PI)

Mechanism of Darunavir (DRV)'s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance.

PMID: 29511083 2018 mBio

Result: HIVWT examined at week 50 of selection (HIVWT-WK50) had acquired three substitutions, M46L, K55N, and V82I, by 50 weeks.

Table: M46L

Detection of minority drug resistant mutations in Malawian HIV-1 subtype C-positive patients initiating and on first-line antiretroviral therapy.

PMID: 29977795 2018 African journal of laboratory medicine

Table: M46L

Discussion: M46I/L is considered a major PI mutation and would increase drug resistance levels to PIs along with other mutations.

Discussion: The natural polymorphism of M46I has been reported to have a replicative advantage for subtype B, while the impact of M46I/L natural polymorphisms on the development of drug resistance in patients is unknown.

Browser Board

Co-occurred Entities

Filtrator